Get Aimovig Prior Authorization Request Form (page 1 Of 2)

Ajovy is given as an injection underneath the skin (subcutaneous) once a month or once every three months. In clinical trials, Ajovy reduced the number of headache days each month for people with both chronic and episodic migraines.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

Ajovy is given as an injection underneath the skin (subcutaneous) once a month or once every three months. In clinical trials, Ajovy reduced the number of headache days each month for people with both chronic and episodic migraines.

If approved by the patient's health plan to take Aimovig® (erenumab-aooe), a patient pays as little as a $5 copay per month, up to an annual maximum benefit. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®.

Ajovy is given as an injection underneath the skin (subcutaneous) once a month or once every three months. In clinical trials, Ajovy reduced the number of headache days each month for people with both chronic and episodic migraines.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

In clinical studies of Aimovig, up to 50% of people with episodic migraine who received 140 mg of the drug reduced their migraine days by at least half over 6 months. About 40% of people who received 70 mg saw similar results.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

If approved by the patient's health plan to take Aimovig® (erenumab-aooe), a patient pays as little as a $5 copay per month, up to an annual maximum benefit. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®.

Aimovig is a brand-name prescription drug that's FDA-approved to prevent migraine headaches in adults. Aimovig can be used to prevent both episodic and chronic migraine headaches.

In clinical studies of Aimovig, up to 50% of people with episodic migraine who received 140 mg of the drug reduced their migraine days by at least half over 6 months. About 40% of people who received 70 mg saw similar results.

If approved by the patient's health plan to take Aimovig® (erenumab-aooe), a patient pays as little as a $5 copay per month, up to an annual maximum benefit. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

Aimovig is a brand-name prescription drug that's FDA-approved to prevent migraine headaches in adults. Aimovig can be used to prevent both episodic and chronic migraine headaches.

In clinical studies of Aimovig, up to 50% of people with episodic migraine who received 140 mg of the drug reduced their migraine days by at least half over 6 months. About 40% of people who received 70 mg saw similar results.

Aimovig can be prescribed in-person or through telemedicine, by primary care doctors and neurologists.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

Aimovig is a brand-name prescription drug that's FDA-approved to prevent migraine headaches in adults. Aimovig can be used to prevent both episodic and chronic migraine headaches.

AIMOVIG was discontinued in most reported cases of constipation with serious complications. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies [see Adverse Reactions (6.1)].

Aimovig can be prescribed in-person or through telemedicine, by primary care doctors and neurologists.

Renewal requests for Aimovig (erenumab) may be approved when the following criteria are met: I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; AND II. Individual has obtained clinical benefit deemed significant by individual or prescriber.

AIMOVIG was discontinued in most reported cases of constipation with serious complications. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies [see Adverse Reactions (6.1)].

AIMOVIG is indicated for the preventive treatment of migraine in adults. The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly.

Aimovig can be prescribed in-person or through telemedicine, by primary care doctors and neurologists.

AIMOVIG was discontinued in most reported cases of constipation with serious complications. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies [see Adverse Reactions (6.1)].

AIMOVIG is indicated for the preventive treatment of migraine in adults. The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly.

Do Medicare prescription drug plans cover Aimovig? Yes. 74% of Medicare prescription drug plans cover this drug.

AIMOVIG is indicated for the preventive treatment of migraine in adults. The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly.

Do Medicare prescription drug plans cover Aimovig? Yes. 74% of Medicare prescription drug plans cover this drug.

The cost for Aimovig subcutaneous solution (aooe 70 mg/mL) is around $786 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Do Medicare prescription drug plans cover Aimovig? Yes. 74% of Medicare prescription drug plans cover this drug.

The cost for Aimovig subcutaneous solution (aooe 70 mg/mL) is around $786 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Your patient's health plan may require a PA for Aimovig®. This checklist may help you organize specific information about your patient's diagnosis and treatment history to complete an Aimovig® PA.

The cost for Aimovig subcutaneous solution (aooe 70 mg/mL) is around $786 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Your patient's health plan may require a PA for Aimovig®. This checklist may help you organize specific information about your patient's diagnosis and treatment history to complete an Aimovig® PA.

Your patient's health plan may require a PA for Aimovig®. This checklist may help you organize specific information about your patient's diagnosis and treatment history to complete an Aimovig® PA.